Thiazolo[3,2-α]-pyrimidine derivatives as calcium antagonists by Balkan, A. et al.
Hacettepe University, Faculty of Pharmacy, Department of Pharmaceutical Chemist ry 1 , 
Hacettepe University, Department of Pharmaco logy 2 , Ankara, Turkey, and 
Universität Regensburg, Institut für Pharmazie 3 
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Some new thiazolo[3,2-a]pyrimidine derivatives were 
prepared refluxing 2-thioxo-l,2,3,4-tetrahydropyrimi-
dine derivatives with phenacyl bromide in glacial acetic 
acid. Calcium antagonistic activities of these com-
pounds were evaluated in K +-depolarized rat aorta, 
using nifedipine as reference compound. 
Derivate des Thiazolo[3,2-a]pyrimidins als Calciumanta-
gonisten 
Neue Derivate des Thiazolo[3,2-a]pyrimidins wurden 
durch Umsetzung von 2-Thioxo-l,2,3,4-tetrahydropyri-
midinen mit Phenacylbromid in siedendem Eisessig 
hergestellt. Die calciumantagonistische Aktivität dieser 
Substanzen wurde an der K+-depolarisierten Ratten-
aorta mit Nifedipin als Vergleichssubstanz geprüft. 
1. Introduction 
1,4-Dihydropyridines, such as nifedipine, nitrendipine and 
amlodipine are widely used in the management of cardiovascu-
lar diseases due to their calcium channel blocking activities 
[1-3]. In order to enhance their intrinsic activity, several 
groups have prepared modifications usually by changing the 
ester groups and/or the substituents on the phenyl nucleus 
[4-6]. We also aimed to synthesize more potent calcium 
channel blocking agents by using the isosters of the 
1,4-dihydropyridine ring, such as 2-thioxo-l,2,3,4-tetrahy-
dropyrimidine. 
For this purpose we synthesized 2-thioxo-l,2,3,4-tetrahy-
dropyrimidines and checked their calcium antagonistic [7, 8] 
and antiaggregating [8] effects in vitro. We later prepared [9] 
two new thiazolo[3,2-a]pyrimidines 3a and 3b from the 
2-thioxo-l,2,3,4-tetrahydropyrimidines la and lb, respective-
ly, with phenacyl bromide according to Takamizawa et al. 
[10] (Scheme 1) and confirmed their structures inter alia by 
1 H — ^ N O E technique [9, 11] indicating that the products 
are 577-isomers. When X H NMR-spectra of the compounds 
were examined it was seen that, due to the double bond of 
the thiazole ring, the singlet of H-2 appeared more downfied 
(approximately 0.3-0.5 ppm) than that of H-5. 
2. Investigations and results 
Here we describe the preparation of compounds 3c-3g using 
the same method [9], in order to investigate their Ca-
antagonistic activities (Scheme). The pertinent efficacies of 
3a-3g were evaluated in the K +-depolarized rat thoracic 
aorta. Each compound produced full relaxation at its maximal 
concentration (n = 5 — 7); their I C 5 0 values are given in the 
Table. In control studies the solvent D M S O was tested: no 
significant relaxation was observed. 
The Ca-antagonistic activities of the starting compounds 
l a - l g had been determined by the radioligand binding 
method and their potencies had been evaluated in terms of 
K i values [7,9] (Table). Comparison of I C 5 0 and the K i values 
indicates that the thiazolo[3,2-a]pyrimidines 3 are stronger 
Ca-antagonists than the starting compounds 1. Even though 
the pharmacological methods are different, the close relation 
between K i and I C 5 0 values obtained for nifedipine (Table) 
Scheme 1 
1 2 "9 3 a - g (5H isomer) 
1 R R' 1 R R' 
a H 4 - C H 3 e H 3 -CI 
b H 4 -OCH3 f H 3 - N 0 2 
c H H g 2-OH 5 - B r 
d H 2 -OCH3 
Table Pharmacological results 
Compound Ki* [mol/1] Compound IC50[mol/l] 
la 4- 1(T 5 3a 5.6 ± 0.3 • K T 6 
lb 5- 1(T 5 3b 8.1 + 0.4- K T 6 
lc 5- 1(T 5 3c 1.4 + 0.3 • K T 6 
Id >1(T 4 3d 1.6 + 0.3 • 1(T 5 
le 2- 1(T 5 3e 2.1 ± 0.5 • K T 7 
If 1(T 4 3f 1.5 + 0.6 • K T 7 
lg K T
5 3g > K T 4 
Nifedipine 1(T 8 6.9 + 0.08 • 1(T 9 
* Ki values represent the concentration of the compounds required to cause 50% inhibition 
of [3H]-PN 200-110 binding in rat skeletal muscle and are taken from previous studies [7,8]. 
may indicate that the results of both methods are com-
parable. 
3. Experimental 
3.1. Chemis t ry 
3.1.1. Devices 
M.p. (uncorr.): Hoover capillary melting point apparatus. UV-spectra: Hitachi 
220 (OH). IR-spectra in K B r : Perkin Elmer 780. *H N M R : Bruker W M 250 
(250 MHz), D 6 - D M S O , T M S as internal standard. Elementary analysis: 
Mikroanalytisches Labor University Regensburg and Tubitak-Mae In-
strumental Analysis Laboratories, Gebze, Turkey. 
l,2,3,4-Tetrahydro-6-methyl-4-(substituted)phenyl-2-thioxo-5-pyrimidine-
carboxylic acid methyl esters lc-g [7,8] and phenacyl bromide (2) were prepared 
as reported [12]. 
3.1.2. Methyl 3-phenyl-5- (substituted)phenyl-7-methyl-5H-thiazolo[3,2-aJpyri-
midine-6-carboxylates 3c-g 
The solutions of 7.5 mmol lc-g and 8 mmol (1.59 g) 2 were refluxed in glacial 
C H 3 C O O H for 6 h and kept overnight at room temp. The mixture was 
concentrated in vacuo and the residue was solidified with ( C 2 H 5 ) 2 0 . The HBr 
salts so obtained were converted to the corresponding bases (5% N a H C 0 3 ) 
which were crystallized from the appropriate solvent. 
3.1.2.1. Methyl 3,5-diphenyl-7-methyl-5/f-thiazolo[3,2-a]pyrimidine-6-
carboxylate (3 c) 
From 1.96 g lc and 2. Yield: 1.68 g (62%). M.p. 162-163 °C 
[ C H 3 C N / H 2 0 (1:2)]. U V (^m a x, lg 8, nm): 207 (4.21), 231 (4.38, sh), 387 (4.58). 
IR (cm - 1 ) : 1710; 1590; 1475. X H N M R (5, ppm): 2.31 (s; 3 H , CH 3 ) , 3.52 (s; 
3 H , O C H 3 ) , 6.16 (s; 1 H , py H-5), 6.61 (d; J = 8 Hz, 2 H aromat., H-2, H-6), 
6.79 (s; 1 H , thia H-2), 7.09-7.12 (m; 3 H aromat., H-3-5), 7.24 (d; J = 8 Hz, 
2 H aromat, H-2', H-6') 7.49-7.53 (m; 3 H aromat, H-3'-5'). 
C 2 1 H 1 8 N 2 0 2 S (362.4) 
Calcd.: C 69.6 H 5.00 N 7.7 
Found: C 69.4 H 5.01 N 7.9 
3.1.2.2. Methyl 3-phenyl-5-(2-methoxyphenyl)-7-methyl-5^-thiazolo[3,2-a] 
pyrimidine-6-carboxylate (3d) 
From 2.19 g Id and 2. Yield: 1.12 g (38%). M.p. 239-240 °C dec. 
[ C 2 H 5 O H / H 2 0 (1:2)]. U V (kmax, lg 8, nm): 207 (4.12), 277 (4.44), 382 (4.60 sh). 
IR (cm- 1): 1710; 1610; 1490. *H N M R (5, ppm): 2.44 (s; 3 H , C H 3 ) , 3.51 (s; 
3 H , C O O C H 3 ) , 3.92 (s; 3 H , O C H 3 ) , 5.39 (s; 1 H py H-5), 5.67 (s; 1 H , thia 
H-2), 6.86-7.13 (m; 3 H aromat, H-4-6), 7.23-7.60 (m; 3 H aromat., H-3, H-2', 
H-6'), 7.65-7.71 (m; 3 H aromat, H-3'-5'). 
C 2 2 H 2 0 N 2 O 3 S (392.5) 
Calcd.: C 67.3 H 5.14 N 7.1 
Found: C 67.7 H 5.53 N 7.4 
3.1.2.3. Methyl 3-phenyl-5-(3-chlorophenyl)-7-methyl-5/f-thiazolo[3,2-a]pyri-
midine-6-carboxylate (3e) 
From 2.22 g le and 2. Yield: 1.9 g (40%). M.p. 138-139 °C [ C 2 H 5 O H / 
H 2 0 (1:2)]. U V (kmax, lg 8, nm): 208 (4.19), 271 (4.78, sh), 387 (4.64). IR (cm" 1): 
1695; 1580; 1475. J H N M R (5, ppm): 2.32 (s; 3 H , C H 3 ) , 3.52 (s; 3 H , O C H 3 ) , 
6.13 (s; 1 H , py H-5), 6.41 (s; 1 H , thia H-2), 6.64 (d; J = 7.5 Hz, 1 H aromat, 
H-6), 6.83 (d; J = 1.8 Hz, 1 H aromat., H-2), 7.20-7.35 (m; 4 H aromat., H-4, 
H-5, H-2', H-6'), 7.44-7.58 (m; 3 H aromat, H-3'-5'). 
C 2 1 H 1 7 C 1 N 2 0 2 S (396.9) 
Calcd.: C 63.5 H 4.32 N 7.1 
Found: C 63.2 H 4.35 N 7.1 
3.1.2.4. Methyl 3-phenyl-5-(3-nitrophenyl)-7-methyl-5/f-thiazolo[3,2-a]pyrimi-
dine-6-carboxylate (3f) 
From 2.30 g If and 2. Yield: 1.29 g (42%). M.p. 153-154 °C [ C 2 H 5 O H / 
H 2 0 ( l : 2 ) ] . U V (^m a x, lg s, nm): 207 (4.20), 249 (4.44), 347 (4.71). IR (cm" 1): 
1700; 1600; 1485. *H N M R (5, ppm): 2.22 (s; 3 H , C H 3 ) , 3.52 (s; 3 H , O C H 3 ) , 
5.50 (s; 1H, py H-5), 6.35 (s; 1 H , thia H-2), 7.14-7.33 (m; 2 H aromat, H-5, 
H-6), 7.39-7.61 (m; 4 H aromat, H-2, H-4, H-2', H-6'), 7.87-8.12 (m; 3 H 
aromat, H-3'-5'). 
C 2 1 H 1 7 N 3 0 4 S (407.5) 
Calcd.: C 61.9 H 4.21 N 10.3 
Found: C 62.2 H 4.48 N 10.0 
3.1.2.5. Methyl 3-phenyl-5-(2-hydroxy-5-bromophenyl)-7-methyl-5//-
thiazolo[3,2-a]pyrimidine-6-carboxylate (3g) 
From 2.67 g lg and 2. Yield: 1.40 g (41%). M.p. 134-135 °C dec. 
[ C H 3 C N / H 2 0 (1:2)]. U V (>.max, lg 8, nm): 207 (4.16), 269 (4.85 sh), 286 (4.66) 
380 (4.76 sh). IR (cm - 1 ) : 1710; 1595; 1490. X H N M R (5, ppm): 2.51 (s; 3 H , 
C H 3 ) , 3.52 (s; 3 H , O C H 3 ) , 5.58 (s; 1 H , py H-5), 6.63 (s; 1 H , thia H-2), 7.17-7.66 
(m; 5 H aromat, H-3, H-4, H-6, H-2', H-6'), 7.88-7.91 (m; 3 H aromat, 
H-3'-5'). 
C 2 1 H 1 7 B r N 2 0 3 S (457.3) 
Calcd.: C 55.2 H 3.75 N 6.1 
Found: C 55.3 H 4.01 N 5.9 
3.2. P h a r m a c o l o g y 
Male rats (200-300 g) were killed by a blow on the head and exsanguinated. 
Strips of thoracic aortae were isolated and mounted in organ baths containing 
20 ml C a 2 +-free K + -rich Krebs solution ([mmol]: NaCl 52, K C l 65, N a H -
C 0 3 25, K H 2 P Ü 4 1.2, glucose 11.5; 37 °C; 95% 0 2 / 5 % C 0 2 . 
° 1 g of resting tension was applied to the tissues and the isometric contractions 
were recorded by a force-displacement transducer (Ugo Basile 7004) on a 
Gemini recorder (model 7070). 
Ca-antagonistic activities of the compounds were evaluated on the basis of 
their ability to relax the aortae precontracted by addition of 1.5 mmolar C a 2 + 
to the K + - r i c h Ca 2 +-free solution. Only one compound was tested in each 
preparation. For comparison nifedipine was used. The potencies of the 
compounds were determined by calculating the concentration producing 50% 
of the maximal relaxation (IC 5 0 ). 
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